Clinical Trial Update: Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus [Phase 3]

View source ↗

Summary

Phase 3 trial comparing MF59-adjuvanted and non-adjuvanted influenza vaccines in patients with chronic pulmonary disease, chronic heart disease, or diabetes mel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Chronic Obstructive Pulmonary Disease
• Diabetes Mellitus

Drugs mentioned

• MF59-adjuvanted influenza vaccine (influenza vaccine adjuvanted with MF59)
• Non-adjuvanted influenza vaccine (influenza vaccine)

Snippet

Sponsor: Chiltern Pesquisa Clinica Ltda | Conditions: H1N1 Influenza Virus, Chronic Pulmonary Disease | Phase 3 | Status: COMPLETED